These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 24462386)

  • 21. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.
    David KA; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
    J Urol; 2007 Aug; 178(2):451-4. PubMed ID: 17561135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
    Kaufman DS; Winter KA; Shipley WU; Heney NM; Wallace HJ; Toonkel LM; Zietman AL; Tanguay S; Sandler HM
    Urology; 2009 Apr; 73(4):833-7. PubMed ID: 19100600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Concurrent radio-chemotherapy in infiltrating cancer of the bladder: a new therapeutic approach?].
    Housset M; Dufour B; Durdux C; Chrétien Y; Méjean A; Baillet F
    Cancer Radiother; 1998 Apr; 2 Suppl 1():67s-72s. PubMed ID: 9749082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Global comparison of radiation and chemotherapy dose-response curves with a test for interaction.
    Lindstrom MJ; Kunugi KA; Kinsella TJ
    Radiat Res; 1993 Aug; 135(2):269-77. PubMed ID: 7690150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study.
    Hussain MH; Glass TR; Forman J; Sakr W; Smith DC; Al-Sarraf M; Jones J; Balcerzak SP; Crawford ED; Grossman HB
    J Urol; 2001 Jan; 165(1):56-60; discussion 60-1. PubMed ID: 11125363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
    Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
    Poortmans PM; Richaud P; Collette L; Ho Goey S; Pierart M; Van Der Hulst M; Bolla M;
    Acta Oncol; 2008; 47(5):937-40. PubMed ID: 18568488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.
    Lin CC; Hsu CH; Cheng JC; Huang CY; Tsai YC; Hsu FM; Huang KH; Cheng AL; Pu YS
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):442-8. PubMed ID: 19307067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer.
    Dreicer R
    Semin Urol Oncol; 2001 Aug; 19(3):180-5. PubMed ID: 11561985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prognosis of efficacy of organ-saving treatment of invasive bladder cancer].
    Ivanov SD; Masliukova EA; Karelin MI; Iamshanov VA; Kovan'ko EG
    Vopr Onkol; 2006; 52(5):565-70. PubMed ID: 17168368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Radiotherapy and chemotherapy in infiltrating bladder tumors].
    Durdux C; Housset M
    Rev Prat; 1997 Feb; 47(4):392-5. PubMed ID: 9114525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
    Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
    Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overview of bladder cancer trials in the Radiation Therapy Oncology Group.
    Shipley WU; Kaufman DS; Tester WJ; Pilepich MV; Sandler HM;
    Cancer; 2003 Apr; 97(8 Suppl):2115-9. PubMed ID: 12673704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response.
    Geh JI; Bond SJ; Bentzen SM; Glynne-Jones R
    Radiother Oncol; 2006 Mar; 78(3):236-44. PubMed ID: 16545878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of failure following surgical resection for malignant pleural mesothelioma.
    Jänne PA; Baldini EH
    Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Defining optimal therapy for muscle invasive bladder cancer.
    Herr HW; Dotan Z; Donat SM; Bajorin DF
    J Urol; 2007 Feb; 177(2):437-43. PubMed ID: 17222605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant treatment for invasive bladder cancer: is it worthwhile?
    Hall RR
    Acta Urol Belg; 1996 May; 64(2):39-42. PubMed ID: 8701809
    [No Abstract]   [Full Text] [Related]  

  • 39. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radical radiotherapy for invasive bladder cancer: What dose and fractionation schedule to choose?
    Pos FJ; Hart G; Schneider C; Sminia P
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1168-73. PubMed ID: 16376486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.